Suppr超能文献

老年患者鼻腔鼻窦间变性大细胞淋巴瘤伴阴性间变性淋巴瘤激酶治疗:罕见病例报告

Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case.

机构信息

Departments of Radiotherapy & Oncology, All India Institute of Medical Sciences, New Delhi, India.

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Head Neck Pathol. 2021 Dec;15(4):1335-1344. doi: 10.1007/s12105-020-01276-3. Epub 2021 Jan 4.

Abstract

Sinonasal anaplastic lymphoma kinase(ALK)-negative anaplastic large cell lymphoma(ALCL) without nodal involvement is exceedingly rare and the rarity of this tumor often engenders diagnostic dilemma. It has been mostly reported in pediatric, adolescent and young adult patients, mostly of Asian origin. A 70-year-old female patient presented with a mass in the left nasal cavity causing nasal obstruction for 5 months. On clinical and radiological examination, there was a 5.7 cm mass in the left nasal cavity, completely obliterating the left ethmoid sinus. Biopsy from the nasal mass showed a poorly differentiated malignant tumour with large cells arranged in sheets. On immunohistochemistry, the tumour cells were positive for leukocyte common antigen(LCA), CD30, CD43, BCL6 and focally for CD5, TIA1, granzyme B and epithelial membrane antigen(EMA), and were negative for CD56, EBV-LMP1, CD79a, PAX5, myeloperoxidase, CD34, CD7, CD4, CD8, CD138, ALK and p63, suggestive of ALK-negative ALCL. Rest of the lymphoma work-up was essentially normal and she had stage IE disease. She was treated with prephase chemotherapy (Vincristine and Prednisolone) followed by 4 cycles of CEOP[Cyclophosphamide, Etoposide (from 2nd cycle onwards), Vincristine and Prednisolone] regimen and local radiotherapy (36 Gy/20 fractions/4 weeks) by intensity modulated radiotherapy(IMRT) technique resulting in complete clinical and radiological response. At last follow-up visit, 15 months from the initial diagnosis, she was alive and disease free. Sinonasal ALK-negative ALCL is a rare tumor which can be effectively treated with a combination of multi-agent CHOP/CHOP-like regimen and local conformal radiotherapy in geriatric patients.

摘要

鼻腔鼻窦间变性淋巴瘤激酶(ALK)阴性间变大细胞淋巴瘤(ALCL)且无淋巴结累及的情况极为罕见,这种肿瘤的罕见性常常导致诊断上的困境。它主要发生在儿科、青少年和年轻成年患者中,主要来自亚洲。一名 70 岁女性患者因左侧鼻腔肿块导致鼻塞 5 个月就诊。临床和影像学检查显示,左侧鼻腔有一个 5.7cm 的肿块,完全阻塞了左侧筛窦。鼻腔肿块的活检显示为低分化恶性肿瘤,大细胞呈片状排列。免疫组化染色显示,肿瘤细胞表达白细胞共同抗原(LCA)、CD30、CD43、BCL6,局部表达 CD5、TIA1、颗粒酶 B 和上皮膜抗原(EMA),而不表达 CD56、EBV-LMP1、CD79a、PAX5、髓过氧化物酶、CD34、CD7、CD4、CD8、CD138、ALK 和 p63,提示为 ALK 阴性 ALCL。其余的淋巴瘤检查基本正常,她患有 IE 期疾病。她接受了前期化疗(长春新碱和泼尼松),随后接受了 4 个周期的 CEOP[环磷酰胺、依托泊苷(从第 2 周期开始)、长春新碱和泼尼松]方案和局部放疗(36Gy/20 次/4 周),采用调强放疗(IMRT)技术,取得了完全的临床和影像学缓解。在最初诊断后的 15 个月的最后一次随访时,她仍然存活且无疾病进展。鼻腔鼻窦 ALK 阴性 ALCL 是一种罕见的肿瘤,在老年患者中,采用多药 CHOP/CHOP 样方案联合局部适形放疗可以有效治疗。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验